telisotuzumab adizutecan + fluorouracil + oxaliplatin + leucovorin + bevacizumab

This is a combination investigational regimen studied in metastatic colorectal cancer (mCRC) that includes **telisotuzumab adizutecan** (ABBV-400, teliso-A), an antibody-drug conjugate targeting c-Met, combined with **fluorouracil (5-FU)**, **oxaliplatin**, **leucovorin**, and **bevacizumab**. Telisotuzumab adizutecan works by delivering a topoisomerase I inhibitor payload specifically to c-Met expressing tumor cells via a monoclonal antibody, resulting in targeted DNA damage and cancer cell death. Fluorouracil is an antimetabolite inhibiting thymidylate synthase, oxaliplatin is a platinum-based DNA crosslinker, leucovorin enhances fluorouracil activity, and bevacizumab is a monoclonal antibody inhibiting vascular endothelial growth factor A (VEGF-A) to suppress angiogenesis. This combination aims to provide both targeted and cytotoxic effects along with anti-angiogenesis.

Other names

telisotuzumab adizutecan + 5-FU + oxaliplatin + leucovorin + bevacizumabteliso-A + FOLFOX + bevacizumab